

Enzyme Kinetics and Inhibition Parameters of Human Leukocyte Glucosylceramidase

Mesut Karataş ¹, Şenol Doğan ², Emrulla Spahiu ^{3*}, Adna Ašić ¹, Larisa Bešić ¹, and Yusuf Turan ¹

¹ International Burch University, Faculty of Engineering and Natural Sciences, Department of Genetics and Bioengineering, Francuske revolucije bb, 71000 Sarajevo, Bosnia and Herzegovina; mesutkara@yahoo.com, adna.asic@ibu.edu.ba, larisa.besic@ibu.edu.ba, and yturan3@yahoo.com

² Leipzig University, Faculty for Physics and Earth Sciences, Peter Debye Institute, Linnéstraße 5, 04103, Leipzig, Germany, senol.dogan@uni-leipzig.de

³*Corresponding author: Independent researcher, Uke Bytyci pn, 20000, Prizren, Kosovo, emrullaspahiu@gmail.com

Abbreviations:

GCase	Glucosylceramidase
GC	Glucosylceramide
GD	Gaucher disease
PD	Parkinson Disease
DLB	Dementia with Lewy bodies
GBA1	Glucosylceramidase beta acid 1
PNPG	para-Nitrophenyl- β -D-glucopyranoside
4-MUG	4-methylumbelliferyl- β -D-glucopyranoside
IC ₅₀	Inhibitor concentration at which the rate is decreased by half

Abstract

Glucosylceramidase (GCase) is a lysosomal enzyme that catalyzes the cleavage of β -glucosidic linkage of glucocerebroside (GC) into glucose and ceramide; thereby, plays an essential function in the degradation of complex lipids and the turnover of cellular membranes.

The growing list of 460 mutations in the gene coding for it—glucosylceramidase beta acid 1 (GBA1)—is reported to abolish its catalytic activity and decrease its enzyme stability, associating it with severe health conditions such as Gaucher disease (GD), Parkinson Disease and Dementia with Lewy bodies.

Although the three-dimensional structure of wild type glucosylceramidase is elucidated, little is known about its features in human cells. Moreover, alternative sources of GCase that prove to be effective in the treatment of diseases with enzyme treatment therapies, impose the need for simple and cost-effective procedures to study the enzyme behaviour. This work, for the first time, shows a well established, yet simple, cost- and time-efficient protocol for the study of GCase enzyme in human leukocytes by the artificial substrate PNPG. Characterization of the enzyme in human leukocytes for activation parameters (optimal pH, Km, and V_{max}) and enzyme inhibition, was done. The results indicate that the optimum pH of GCase enzyme with PNPG is 5.1. The K_m and V_{max} values were 12.6mM and 333 U/mg, respectively. Gluconolactone successfully inhibits GCase in a competitive manner, with a K_i value of 0.023 mM and IC₅₀ of 0.047 mM. Glucose inhibition was uncompetitive with a K_i of 1.94 mM and IC₅₀ of 55.3 mM. This is the first report for the inhibitory effect of glucose, δ -gluconolactone on leukocyte GCase activity.

Keywords: glucosylceramidase, glucosylceramide, pnpg, human leukocyte, enzyme kinetics, inhibition parameters, gaucher disease, glucose, gluconolactone

Introduction

Glucosylceramidase (GCase, EC 3.2.1.45) is a lysosomal enzyme with 497 amino acids and three discontinuous domains [1]. It is a β -glucosidase enzyme that catalyzes the cleavage of glucosylceramide (GC) into glucose and ceramide [2]; thereby, it plays a vital function in the degradation of complex lipids and the turnover of cellular membranes [3]. The main cellular compartment of GCase is the lysosomal membrane [4]. The activator proteins Saposin A and C, synergistically facilitate the interaction between the lipid substrate and enzyme, resulting in increased GCase enzymatic activity [5, 6]. The substrate (GC) is synthesized from the degradation of glycosphingolipids in the membranes of apoptotic white blood cells and senescent red blood cells [7].

Gaucher disease (GD, OMIM#230800) is the most protracted health condition related to defective GCase activity [6]. The recent studies, however, further associated GCase with severe health conditions such as Parkinson's Disease (PD, OMIM#168600) [8], Dementia with Lewy bodies (DLB, OMIM# 127750) [9] and colorectal cancer [10]. GCase is encoded by the housekeeping gene glucosylceramidase beta acid 1 (*GBA1*, OMIM*606463) with cytogenetic location 1q21 [11]. More than 460 mutations are reported to disrupt the *GBA1* gene [12, 13], thereby abolishing its catalytic activity [14] and decreasing enzyme stability [15]. The improper breakdown of highly hydrophobic GC results in its accumulation in the lysosomes of macrophages, leading to dysfunctions in spleen, liver, and bone marrow [16, 17]. The abnormal accumulation and storage of these substances damage tissues and organs, causing the clinical manifestations of GD [18], which is the most frequent lysosomal storage disorder [19, 20]. GD is shown to produce a continuum of different clinical conditions, from the fatal perinatal disorder to the asymptomatic one [21]. The efficiency of enzyme replacement therapy (ERT) in GD, has led to extensive studies carried out in alternative sources of GCase [22, 23]. GD has a global occurrence of 1:50,000 [24], but due to the founder effect, it shows a higher prevalence in Ashkenazi Jewish (Eastern European), Spanish, and Portuguese populations [25]. On the other hand, PD is a closely related neurological complication of GD, which is seen with carriers of heterozygous mutations in the *GBA1* gene being susceptible to developing it [8]. Recent genetic and pathological reports suggest *GBA1* mutations as critical risk factors for DLB as well [26].

Detection of GD by GCase assay is done in a variety of human tissues, including the liver [27], brain [5], and placenta [28]. Although any human tissue can be used to study GCase activity, in our study, we used human blood as the most readily available one. *In vitro*, GCase is solubilized from membranes by the extraction of lysosomal membranes using a detergent—TritonX-100 [29–31]. The non-ionic detergent Triton X-100 removes the endogenous natural lipid activators that are found in lysosomal membranes [32], consequently rendering Glucosylceramidase inactive [29]. Therefore, the reconstitution of GCase activity requires the inclusion of an anionic detergent—sodium taurocholate [39–47]—in the assay medium. The detergent sodium taurocholate is an essential component of GCase assay and can be used with artificial substrates to measure the GCase activity with minimal interference from other β -glucosidases [30]. Sodium taurocholate inhibits nonspecific β -glucosidase, which cannot hydrolyze glucocerebroside and stimulate GCase activity [41]. Therefore a crude protein extract is suitable without the need for a purified protein. The lysosomal GCase, *in vivo*, is active on its natural lipid substrate glucosylceramide. *In vitro*, artificial substrates such as PNPG (para-Nitrophenyl- β -D-glucopyranoside) [46–48] and 4-MUG (4-methylumbelliferyl- β -D-glucopyranoside) [49–51] are very convenient ways of studying its activity due to a high yield of products that strongly absorb around 400 nm [53].

In this work, GCase enzyme activity in human leukocytes by using an artificial substrate is studied and for the first time the inhibitory effects of glucose and δ -gluconolactone are shown. A novel protocol was designed for brief biochemical characterization of activation parameters (optimal pH, K_m , and V_{max}) and enzyme inhibition.

Materials and Methods

Chemicals and samples

p-nitrophenyl- β -D-glucopyranoside (PNPG), pure sodium taurocholate (6 mg/ml), Triton X-100, glucose, and D-gluconolactone (D-glucono-1,5-lactone), were obtained from Sigma-Aldrich (Germany). Additionally, we used pure sodium acetate buffer (50 mM; 0.4355% w/v CH₃COO Na/, 0.1089% w/v CH₃COOH, pH 5), and lysis buffer (155 mmol/L NH₄Cl; 10 mmol/L NaHCO₃; 0.1 mmol/L EDTA) obtained from Semikem (Bosnia and Herzegovina). Blood samples were acquired using the guidelines and approval of the University of Burch Research Ethics Committee (30052016). Written informed consent was obtained from two healthy adult male donors. Whole EDTA blood (10 ml) was collected aseptically.

Isolation of Leukocytes

Leukocytes were isolated by centrifugation after specific lysis of erythrocytes, according to the method of Peters et al. [42]. Aseptically collected whole EDTA blood (10 ml) was centrifuged at 1500g at 4°C for ten minutes, followed by the removal of plasma. The original blood volume was restored with 0.9% (w/v) NaCl solution and the blood suspension was transferred to a 50 ml conical centrifuge tube, followed by the addition of 40 ml cold hypotonic lysis buffer. The tube was left to stand on the ice and occasionally mixed for approximately ten minutes. The suspension was centrifuged again at 1500g at 4°C for five minutes. Leukocytes formed a small, firm pellet on the side of the tube while the erythrocyte ghosts formed a large loose pellet at the bottom of the tube. Both the hemoglobin-containing supernatant and the loose red cell ghosts were removed by aspiration using a Pasteur pipette. Leukocyte pellet was suspended in 5 ml cold hypotonic lysis buffer. The tube was left to stand on the ice. After 10 minutes, the cell suspension was diluted up to 50 ml with cold 0.9% (w/v) NaCl solution and centrifuged again at 1500g at 4°C for five minutes. The supernatant was discarded, and the leukocyte pellet was suspended in 10 ml 0.9% (w/v) NaCl solution followed by centrifugation at 1500g at 4°C for ten minutes. The supernatant was removed entirely, and samples were stored at -80°C for further use. A step by step protocol is uploaded at protocols.io (dx.doi.org/10.17504/protocols.io.bcv2iw8e) [54]

Extraction of GCase from leukocyte pellet

GCase extraction protocol is modified from Kara et al. [55]. Leukocyte cell pellets equivalent to 10 ml of whole blood were thawed and suspended in 1.0 ml of 0.1% (v/v) detergent TritonX-100, and subjected to six cycles of freezing-thawing by alternating tubes, at approximately three-minute intervals, using a dry-ice/ethanol bath and water bath (-70°C / 27°C). The total homogenate was centrifuged at 2100g for 5 minutes at 10°C and supernatant was put into a clean tube in an ice bath for assay. Protein concentration was estimated by the Bradford method, using bovine serum albumin as standard [56].

Leukocyte Glucosylceramidase Assay

Glucosylceramidase activity was determined spectrophotometrically using 140 μ l assay mixtures. The standard reaction mixture consisted of 70 μ l of enzyme solution and 70 μ l of 5 mM PNPG substrate in 50 mM sodium acetate buffer (pH 5.0), sodium taurocholate was dissolved in the substrate solution [30]. After incubation at 37°C for 45 min, the reaction was terminated by the addition of 70 μ l of 0.5 M sodium carbonate (Na₂CO₃, pH 10.3). Absorbance was read at 400 nm against the blank solution containing substrate buffer instead of the enzyme extract. One unit of GCase activity was defined as the amount of enzyme required to release one μ mol of *p*-nitrophenol from PNPG per minute (1 U), at 37°C and pH 5.0.

In vitro Inhibition Studies and Determination of Kinetic Parameters

All the samples were assayed in the presence of pure sodium taurocholate at pH 5.0. The substrate concentrations for each sample were: 0.71, 1.07, 1.43, 1.79, and 2.50 mmol per liter. Incubations were carried out at 37°C for 45 min. The K_m and V_{max} were obtained through the Lineweaver-Burk plot, whereby the best fit lines were calculated by linear regression analysis. Inhibition experiments were performed using PNPG as substrate, and different final concentrations of δ -gluconolactone, glucose as possible inhibitors. A double reciprocal Lineweaver-Burk plot was used to calculate the parameters. The activity of the β -Glucosylceramidase at four different concentrations of each inhibitor was determined by regression analysis. Results are expressed as % activity, assuming 100% enzyme activity in the absence of an inhibitor. In the presence of possible inhibitors, % activity was calculated by using the following equation: % activity = 100-[(A₀-A_i)/A₀)] x100.

where A₀ is the initial GCase activity (without inhibitor), and A_i is the GCase activity with the inhibitor. The inhibitor concentration that reduces the enzymatic activity by 50% (I₅₀ values) was determined from the plots.

Results and Discussion

GCase Extraction and Optimization of Stability

Protein studies require proper preservation of proteins in order to work with the same quality of protein throughout the steps [57]. We performed the optimization study for the stability of GCase in leukocyte homogenate in the course of storage in -20°C frost-free freezer. It was observed that the activity of GCase, exhibits only minor changes after ten and twenty days of storage, in the presence of pure sodium taurocholate (Figure A1). In our study, GCase present in the crude protein extract was partially purified. However, the fact that cleavage of PNPG substrate is only possible by GCase, makes our way a convenient one to study the enzyme kinetics of GCase. Furthermore, UV-vis spectroscopy with an absorbance signal higher than 320nm is widely used to study protein preparations and monitoring enzyme activity [58]. In our case, the product of the catalyzed reaction, p-nitrophenol, was continuously released from PNPG, and this product strongly absorbed light at 400 nm [53]. With this theoretical framework, we developed a simple, cost- and time-efficient technique to study the activity of this enzyme with high importance in many diseases and industry.

Determination of Optimal pH

The conformational stability and catalytic activity of enzymes are in direct relationship to their pH [59]. To determine the optimal pH value for the hydrolysis of PNPG by leukocyte GCase, we examined the effects of variable pH (4.0-5.5) at a constant substrate concentration (5mM). Figure 1.A shows the pH activity curve of leukocyte GCase assayed in the presence of sodium taurocholate. Leukocyte GCase was optimally active at pH 5.1, after which the enzyme activity started to decline (Figure 1.B). The optimal pH of GCase activity from different sources and different substrate is reported to be in 4.7–5.9 intervals [60], which is consistent with its lysosomal function and our finding.

Determination of Glucosylceramidase Km and Vmax for PNPG substrate

The Michaelis constant (K_m) is a measure of the affinity of the enzyme towards the substrate, with smaller values representing higher affinity. The Michaelis constant (K_m) and the maximum rate (V_{max}) of leukocyte GCase were obtained through the Lineweaver-Burk plot (Figure 1.B) with artificial substrate PNPG in concentrations ranging from 0.71 mM to 2.50 mM. K_m and V_{max} values were found to be 12.6 mM and 333 U/mg, respectively, in reasonable agreement with previously reported (593 mM) studies [53].

In vitro Enzyme Inhibitor Studies

The inhibition study was performed using the PNPG as a substrate. Inhibitors were defined to be gluconolactone and glucose. The results indicated that gluconolactone was the most effective inhibitor acting in competitively with a IC_{50} value of 0.047 mM (Figure 2.A) and K_i value of 0.023 mM (Figure 2B). The changing apparent K_m to higher values in higher gluconolactone concentrations is an indicator of competitive inhibition (Table 2). A report from placental cells has shown similar results [45]. However, as can be seen in Table 2, glucose was shown to be an uncompetitive inhibitor of PNPG hydrolysis, with a IC_{50} value of 55.3 mM (Figure 3A) and K_i value of 1.94 mM (Figure 3B). Based on literature, this is the first study to investigate gluconolactone and glucose inhibition in human leukocyte GCase. However, the inhibition kinetics of β -glucosidase (EC3.2.1.21) from several plants, fungi and especially microorganisms [62–66] has extensively been studied using glucose as an inhibitor, since glucose inhibition of β -glucosidase is undesirable if the enzymatic hydrolysis of cellulose is performed as an industrial process [67, 68].

Table 2. Kinetic parameters of Glucosylceramidase in different concentration of gluconolactone and glucose

Gluconolactone	I_0	I_1	I_2	Conclusion
V_{max} and V_{max}^{app}	333.3	333.3	333.3	V_{max} unchanged
K_m and K_m^{app}	3.6	5.6	8.6	The apparent K_m increased
K_i		0.023	0.119	Competitive Inhibition
Glucose	I_0	I_1	I_2	Conclusion
V_{max} and V_{max}^{app}	333.3	90.9	13.5	V_{max} decreased
K_m and K_m^{app}	8.9	2.6	0.27	The apparent K_m decreased
K_i		2.09	1.94	Uncompetitive Inhibition

Conflict of Interest:

The authors declare no conflict of interest

REFERENCES

1. Smith L, Mullin S, Schapira AHV (2017) Insights into the structural biology of Gaucher disease. *Exp Neurol* 298:180–190. <https://doi.org/10.1016/j.expneurol.2017.09.010>
2. Beutler E (1992) Gaucher disease: new molecular approaches to diagnosis and treatment. *Science* 256:794–799. <https://doi.org/10.1126/science.256.5058.794>
3. Magalhaes J, Gegg ME, Migdalska-Richards A, et al (2016) Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. *Hum Mol Genet* 25:3432–3445. <https://doi.org/10.1093/hmg/ddw185>
4. Yap TL, Jiang Z, Heinrich F, et al (2015) Structural Features of Membrane-bound Glucocerebrosidase and α -Synuclein Probed by Neutron Reflectometry and Fluorescence Spectroscopy. *J Biol Chem* 290:744–754. <https://doi.org/10.1074/jbc.M114.610584>
5. Alroy J, Lyons JA (2014) Lysosomal storage diseases. *J Inborn Errors Metab Screen* 2:2326409813517663
6. Grabowski GA, Gaft S, Horowitz M, Kolodny EH (1990) Acid β -Glucosidase: Enzymology and Molecular Biology of Gaucher Disease. *Crit Rev Biochem Mol Biol* 25:385–414
7. Glew RH, Basu A, LaMarco KL, Prence EM (1989) Mammalian glucocerebrosidase: implications for Gaucher's disease. In: *Pathology Reviews*. 1989. Springer, pp 3–23
8. Kim H-J, Jeon B, Song J, et al (2016) Leukocyte glucocerebrosidase and β -hexosaminidase activity in sporadic and genetic Parkinson disease. *Parkinsonism Relat Disord* 23:99–101. <https://doi.org/10.1016/j.parkreldis.2015.12.002>
9. Goker-Alpan O, Giasson BI, Eblan MJ, et al (2006) Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. *Neurology* 67:908–910. <https://doi.org/10.1212/01.wnl.0000230215.41296.18>
10. Karatas M, Turan Y, Kurtovic-Kozaric A, Dogan S (2016) Analysis of Gaucher Disease Responsible Genes in Colorectal Adenocarcinoma. *J Biom Biostat* 7:.. <https://doi.org/10.4172/2155-6180.1000314>
11. Cormand B, Montfort M, Chabás A, et al (1997) Genetic fine localization of the β -glucocerebrosidase (GBA) and prosaposin (PSAP) genes: implications for Gaucher disease. *Hum Genet* 100:75–79. <https://doi.org/10.1007/s004390050468>
12. Sheth J, Bhavsar R, Mistri M, et al (2019) Gaucher disease: single gene molecular characterization of one-hundred Indian patients reveals novel variants and the most prevalent mutation. *BMC Med Genet* 20:31. <https://doi.org/10.1186/s12881-019-0759-1>
13. Dogan S, Kurtovic-Kozaric A, Karlı, Gunay (2016) The Detection of Extremely High and Low Expressed Genes by EGEFAAlgorithm in Invasive Breast Cancer. <https://doi.org/10.4172/2155-6180.1000286>
14. Meivar-Levy I, Horowitz M, Futerman AH (1994) Analysis of glucocerebrosidase activity using N-(1-[¹⁴C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease. *Biochem J* 303:377–382
15. Grace ME, Newman KM, Scheinker V, et al (1994) Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression. *J Biol Chem* 269:2283–2291

16. Glew RH, Basu A, LaMarco KL, Prence EM (1989) Mammalian glucocerebrosidase: implications for Gaucher's disease. In: *Pathology Reviews*. 1989. Springer, pp 3–23
17. Spahiu E (2015) ATR-FTIR Evaluation of Structural and Functional Changes on Murine Macrophage Cells Upon Activation and Suppression by Immuno-Therapeutic Oligodeoxynucleotides. Thesis, Middle East Technical University
18. Beutler E, Demina A, Gelbart T (1994) Glucocerebrosidase mutations in Gaucher disease. *Mol Med* 1:82
19. A Z, A K, T G, et al (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. *Medicine (Baltimore)* 71:337–353
20. Dogan S, Mermel E (2017) Comparison of the Hemoglobin Amount between Old and Young Persons in Bosnia and Herzegovina. *J Biom Biostat* 08: <https://doi.org/10.4172/2155-6180.1000337>
21. Pastores GM, Hughes DA (1993) Gaucher Disease. In: Adam MP, Ardinger HH, Pagon RA, et al (eds) *GeneReviews®*. University of Washington, Seattle, Seattle (WA)
22. Naphatsamon U, Ohashi T, Misaki R, Fujiyama K (2018) The Production of Human β -Glucocerebrosidase in Nicotiana benthamiana Root Culture. *Int J Mol Sci* 19:1972. <https://doi.org/10.3390/ijms19071972>
23. Bešić L, Ašić A, Muhović I, et al (2017) Purification and Characterization of β -Glucosidase from *Brassica oleracea*. *J Food Process Preserv* 41:
24. De Fost M, Aerts JM, Hollak CE (2003) Gaucher disease: from fundamental research to effective therapeutic interventions. *Neth J Med* 61:3–8
25. Pastores GM, Hughes DA (1993) Gaucher Disease. In: Adam MP, Ardinger HH, Pagon RA, et al (eds) *GeneReviews®*. University of Washington, Seattle, Seattle (WA)
26. Yang N-Y, Lee Y-N, Lee H-J, et al (2013) Glucocerebrosidase, a new player changing the old rules in Lewy body diseases. *Biol Chem* 394:807–818. <https://doi.org/10.1515/hsz-2012-0322>
27. Raghavan SS, Topol J, Kolodny EH (1980) Leukocyte β -glucosidase in homozygotes and heterozygotes for Gaucher disease. *Am J Hum Genet* 32:158
28. Huang C, Freter C (2015) Lipid metabolism, apoptosis and cancer therapy. *Int J Mol Sci* 16:924–949
29. Glew RH, Basu A, Prence E, et al (1986) The Effects of Acidic Lipids and Heat-Stable Factor on the Physical-Chemical and Kinetic Properties of Glucocerebrosidase. In: *Enzymes of Lipid Metabolism II*. Springer, pp 361–370
30. Magalhaes J, SáMiranda MC, Pinto R, et al (1984) Sodium taurocholate effect on β -glucosidase activity: a new approach for identification of Gaucher disease using the synthetic substrate and leucocytes. *Clin Chim Acta* 141:111–118
31. Wattiaux R, De Duve C (1956) Tissue fractionation studies. 7. Release of bound hydrolases by means of Triton X-100. *Biochem J* 63:606
32. Glew RH, Rosenthal MD (2006) *Clinical Studies in Medical Biochemistry*. Oxford University Press
33. Butcher BA, Gopalan V, Lee RE, et al (1989) Use of 4-heptylumbelliferyl- β -d-glucoside to identify Gaucher's disease heterozygotes. *Clin Chim Acta* 184:235–242
34. Daniels LB, Glew RH (1982) beta-Glucosidase assays in the diagnosis of Gaucher's disease. *Clin Chem* 28:569–577

35. Ho MW (1973) Identity of 'acid' β -glucosidase and glucocerebrosidase in human spleen. *Biochem J* 136:721–729
36. Ho MW, O'Brien JS (1971) Gaucher's Disease: Deficiency of "cid" β -Glucosidase and Reconstitution of Enzyme Activity In Vitro. *Proc Natl Acad Sci* 68:2810–2813
37. Hyun JC, Misra RS, Greenblatt D, Radin NS (1975) Synthetic inhibitors of glucocerebroside β -glucosidase. *Arch Biochem Biophys* 166:382–389
38. Lieberman RL (2011) A guided tour of the structural biology of Gaucher disease: Acid- β -glucosidase and saposin C. *Enzyme Res* 2011:
39. Michelin K, Wajner A, Bock H, et al (2005) Biochemical properties of β -glucosidase in leukocytes from patients and obligate heterozygotes for Gaucher disease carriers. *Clin Chim Acta* 362:101–109
40. Michelin K, Wajner A, Goulart L da S, et al (2004) Biochemical study on β -glucosidase in individuals with Gaucher's disease and normal subjects. *Clin Chim Acta* 343:145–153
41. Peters SP, Coyle P, Glew RH (1976) Differentiation of β -glucocerebrosidase from β -glucosidase in human tissues using sodium taurocholate. *Arch Biochem Biophys* 175:569–582
42. Peters SP, Lee RE, Glew RH (1975) A microassay for Gaucher's disease. *Clin Chim Acta* 60:391–396
43. Strasberg PM, Lowden JA (1982) The assay of glucocerebrosidase activity using the natural substrate. *Clin Chim Acta* 118:9–20
44. Wenger DA, Clark C, Sattler M, Wharton C (1978) Synthetic substrate is s-glucosidase activity in leukocytes: A reproducible method for the identification of patients and carriers of Gaucher's disease. *Clin Genet* 13:145–153
45. Yu-Bin C, Glew RH, Diven WF, Lee RE (1980) Comparison of various β -glucosidase assays used to diagnose Gaucher's disease. *Clin Chim Acta* 105:41–50
46. Fishman WH, Springer B, Brunetti R (1948) Application of an improved glucuronidase assay method to the study of human blood β -glucuronidase. *J Biol Chem* 173:449–456
47. Kato K, Yoshida K, Tsukamoto H, et al (1960) Synthesis of p-Nitrophenyl β -D-Glucopyranosiduronic Acid and Its Utilization as a Substrate for the Assay of β -Glucuronidase Activity. *Chem Pharm Bull (Tokyo)* 8:239–242
48. Szasz G (1967) Comparison between p-nitrophenyl glucuronide and phenolphthalein glucuronide as substrates in the assay of β -glucuronidase. *Clin Chem* 13:752–759
49. Beutler E, Kuhl W (1970) The diagnosis of the adult type of Gaucher's disease and its carrier state by demonstration of deficiency of β -glucosidase activity in peripheral blood leukocytes. *J Lab Clin Med* 76:747–755
50. Grabowski GA, Dagan A (1984) Human lysosomal β -glucosidase: Purification by affinity chromatography. *Anal Biochem* 141:267–279
51. Ho MW, Seck J, Schmidt D, et al (1972) Adult Gaucher's disease: kindred studies and demonstration of a deficiency of acid beta-glucosidase in cultured fibroblasts. *Am J Hum Genet* 24:37
52. Maret A, Salvayre R, Potier M, et al (1988) Comparison of Human Membrane-Bound β -Glucosidases: Lysosomal Glucosylceramide- β -Glucosidase and Non-Specific β -Glucosidase. In: *Lipid Storage Disorders*. Springer, pp 57–61

53. Paal K, Ito M, Withers SG (2004) *Paenibacillus* sp. TS12 glucosylceramidase: kinetic studies of a novel sub-family of family 3 glycosidases and identification of the catalytic residues. *Biochem J* 378:141–149. <https://doi.org/10.1042/BJ20031028>
54. Karatas M, Dogan S, Spahiu E, A Ašić, L Bešić, Y Turan (2020) Preparation of leukocytes by differential lysis of erythrocytes. *Protocols.io* <https://doi.org/10.17504/protocols.io.bcv2iw8e>
55. Kara HE, Sinan S, Turan Y (2011) Purification of beta-glucosidase from olive (*Olea europaea* L.) fruit tissue with specifically designed hydrophobic interaction chromatography and characterization of the purified enzyme. *J Chromatogr B* 879:1507–1512. <https://doi.org/10.1016/j.jchromb.2011.03.036>
56. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72:248–254
57. Raynal B, Lenormand P, Baron B, et al (2014) Quality assessment and optimization of purified protein samples: why and how? *Microb Cell Factories* 13:. <https://doi.org/10.1186/s12934-014-0180-6>
58. Raynal B, Lenormand P, Baron B, et al (2014) Quality assessment and optimization of purified protein samples: why and how? *Microb Cell Factories* 13:. <https://doi.org/10.1186/s12934-014-0180-6>
59. Xia W, Xu X, Qian L, et al (2016) Engineering a highly active thermophilic β -glucosidase to enhance its pH stability and saccharification performance. *Biotechnol Biofuels* 9:147. <https://doi.org/10.1186/s13068-016-0560-8>
60. Tan YL, Genereux JC, Pankow S, et al (2014) ERdj3 Is an Endoplasmic Reticulum Degradation Factor for Mutant Glucocerebrosidase Variants Linked to Gaucher's Disease. *Chem Biol* 21:967–976. <https://doi.org/10.1016/j.chembiol.2014.06.008>
61. Grabowski GA, Gatt S, Kruse J, Desnick RJ (1984) Human lysosomal β -glucosidase: kinetic characterization of the catalytic, aglycon, and hydrophobic binding sites. *Arch Biochem Biophys* 231:144–157
62. Ašić A, Bešić L, Muhović I, et al (2015) Purification and characterization of β -glucosidase from *Agaricus bisporus* (white button mushroom). *Protein J* 34:453–461
63. Bešić L, Ašić A, Muhović I, et al (2017) Purification and Characterization of β -Glucosidase from *Brassica oleracea*. *J Food Process Preserv* 41:
64. Teugjas H, Välijamäe P (2013) Selecting β -glucosidases to support cellulases in cellulose saccharification. *Biotechnol Biofuels* 6:105
65. Uchiyama T, Miyazaki K, Yaoi K (2013) Characterization of a novel β -glucosidase from a compost microbial metagenome with strong transglycosylation activity. *J Biol Chem* 288:18325–18334
66. Turan Y, Zheng M (2005) Purification and characterization of an intracellular β -glucosidase from the methylotrophic yeast *Pichia pastoris*. *Biochem Mosc* 70:1363–1368
67. Chan CS, Sin LL, Chan K-G, et al (2016) Characterization of a glucose-tolerant β -glucosidase from *Anoxybacillus* sp. DT3-1. *Biotechnol Biofuels* 9:174
68. Pei J, Pang Q, Zhao L, et al (2012) *Thermoanaerobacterium thermosaccharolyticum* β -glucosidase: a glucose-tolerant enzyme with high specific activity for cellobiose. *Biotechnol Biofuels* 5:31

Figure Captions

Figure 1.(A) The optimal pH for Human Leukocyte Glucosylceramidase (GCase) activity, is measured to be 5.1. The influence of varying pH values on the activity was determined by using sodium acetate buffer in the pH range of 4.0 to 5.5. **(B)** Lineweaver-Burk plot for Michaelis constant determination of GCase for different *p*-nitrophenyl- β -D-glucopyranoside (PNPG) substrate concentrations (0.71 mM-2.50 mM) in sodium acetate buffer (50mM, pH 5.0), reveals a K_m of 12.6 mM and V_{max} of 333 U/mg. All samples were assayed in the presence of 6 mg / ml sodium taurocholate and 70 μ l of enzyme solution.


Figure 2.(A) The plot of relative activity (%) of Human Leukocyte Glucosylceramidase (GCase) in different concentrations of δ -gluconolactone **(B)** Lineweaver-Burk plot analysis of GCase inhibited by increasing the concentration of δ -gluconolactone. GCase activity was measured with *p*-nitrophenyl- β -D-glucopyranoside (PNPG) as the substrate, in the absence (no-inhibitor) or presence of the following concentration of δ -gluconolactone concentrations: (Inhibitor 1) 0.0128 mM; (Inhibitor 2) 0.0642 mM. The intercept of the plots indicates competitive inhibition for δ -gluconolactone (See Appendix A2 for inlet of intersection).

Figure 3.(A) The relative activity (%) curve of the Glucosylceramidase (GCase) in the presence of different glucose concentrations **(B)** Lineweaver-Burk plot analysis of the GCase inhibited by increasing the concentration of glucose. GCase activity was measured with *p*-nitrophenyl- β -D-glucopyranoside (PNPG) as the substrate, in the absence (no-inhibitor) or presence of the following concentration of glucose concentrations: (Inhibitor-1) 5.07 mM; (Inhibitor-2) 62.8 mM. Successful enzyme activity inhibition in an uncompetitive manner of glucose has been demonstrated. (See Appendix A2 for inlet of intersection).


Figure A1. Glucosylceramidase (GCase) enzyme stability in leukocyte homogenate storage at -20°C. Enzyme activity at day 0 was taken as 100%, and the remaining results were normalized according to this value.


Figure A2. Inlet of intersection for Lineweaver-Burk plot analysis in Figures 2B and 3B for the GCase inhibition by increasing concentration of **(A)** δ -gluconolactone **(B)** glucose.


Optimal pH




p-NPG









Glucose inhibition

